Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Correlating concerted cations with oxygen redox in rechargeable batteries.
Journal: Chemical Society reviews
Published: February 28, 2024
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2.
Journal: Therapeutic advances in musculoskeletal disease
Published: March 23, 2023
Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
Journal: Clinical rheumatology
Published: July 12, 2022
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
Journal: Advances in therapy
Published: February 01, 2022
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results.
Journal: Clinical rheumatology
Published: January 27, 2022
Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
Journal: The Lancet. Rheumatology
Published: January 13, 2022
Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
Journal: The Journal of rheumatology
Published: November 19, 2021
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
Journal: Rheumatology (Oxford, England)
Published: May 14, 2021
Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks.
Journal: BMC rheumatology
Published: March 23, 2021
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial.
Journal: Rheumatology and therapy
Published: September 25, 2020
Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey.
Journal: Clinical rheumatology
Published: September 10, 2020
Last Updated: 09/26/2026